Logo image of ALTHX.PA

THERANEXUS SADIR (ALTHX.PA) Stock Price, Quote, News and Overview

EPA:ALTHX - Euronext Paris - Matif - FR0013286259 - Common Stock - Currency: EUR

0.49  +0.01 (+2.51%)

ALTHX.PA Quote, Performance and Key Statistics

THERANEXUS SADIR

EPA:ALTHX (3/7/2025, 7:00:00 PM)

0.49

+0.01 (+2.51%)

Sector
GICS SectorHealth Care
GICS IndustryPharmaceuticals
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS SubIndustryPharmaceuticals
Statistics
52 Week High1.35
52 Week Low0.46
Market Cap3.80M
Shares7.76M
Float5.73M
Yearly DividendN/A
Dividend YieldN/A
PEN/A
Fwd PEN/A
Earnings (Next)04-29 2025-04-29/amc
IPO10-30 2017-10-30


ALTHX.PA short term performance overview.The bars show the price performance of ALTHX.PA in the last week, last 2 weeks, last month, last 3 and 6 months. 1 week 2 week 1 month 3 months 6 months 0 -5 -10 -15 -20

ALTHX.PA long term performance overview.The bars show the price performance of ALTHX.PA in the last 1, 2 and 3 years. 1 year 2 years 3 years -20 -40 -60 -80

The current stock price of ALTHX.PA is 0.49 EUR. In the past month the price decreased by -9.26%. In the past year, price decreased by -55.13%.

THERANEXUS SADIR / ALTHX Daily stock chart

ALTHX.PA Competitors/Peers

The largest stocks on the EU markets in the "Pharmaceuticals" sub-industry
Full List
Symbol
Name
TA
FA
PE
Market Cap
1LLY.MI ELI LILLY & CO 67 760.43B
LLY.DE ELI LILLY & CO 66.98 760.15B
ZEG.DE ASTRAZENECA PLC 21.82 446.45B
JNJ.DE JOHNSON & JOHNSON 16.81 372.31B
1JNJ.MI JOHNSON & JOHNSON 16.61 367.98B
NOV.DE NOVO NORDISK A/S-B 26.21 355.97B
SNW.DE SANOFI 14.32 275.64B
SAN.PA SANOFI 14.27 274.84B
1SAN.MI SANOFI 14.19 273.18B
6MK.DE MERCK & CO. INC. 12.64 224.82B
1MRKX.MI MERCK & CO. INC. 12.47 221.79B
1PFE.MI PFIZER INC 8.6 139.42B

About ALTHX.PA

Company Profile

ALTHX logo image Theranexus SA engages in the design and development of drug candidates affecting the interaction between neurons and glial cells. The company is headquartered in Lyon, Auvergne-Rhone-Alpes and currently employs 12 full-time employees. The company went IPO on 2017-10-30. The firm is a biopharmaceutical entity that develops drug candidates to be used in the treatment of central nervous system (CNS) disorders, including epilepsy, narcolepsy, Parkinson's disease, Alzheimer's disease, neuropathic pain and psychiatric disorders. Its patented technology is aimed at increasing the efficacy of CNS drugs, which are approved and available on the market. The firm's technology is protected, scalable and versatile, and used to generate high value-added proprietary drug candidates for different conditions, while reducing time-to-market and market entry costs and risks in comparison with standard drug development processes. Theranexus SA operates in the domestic market.

Company Info

THERANEXUS SADIR

60, Avenue Rockefeller - Pepiniere Laennec

Lyon AUVERGNE-RHONE-ALPES FR

Employees: 17

Company Website: https://www.theranexus.com/

Investor Relations: http://www.theranexus.com/fr/actionnaires/documents.html

Phone: 33188897031

THERANEXUS SADIR / ALTHX.PA FAQ

What is the stock price of THERANEXUS SADIR today?

The current stock price of ALTHX.PA is 0.49 EUR. The price increased by 2.51% in the last trading session.


What is the ticker symbol for THERANEXUS SADIR stock?

The exchange symbol of THERANEXUS SADIR is ALTHX and it is listed on the Euronext Paris - Matif exchange.


On which exchange is ALTHX.PA stock listed?

ALTHX.PA stock is listed on the Euronext Paris - Matif exchange.


What is the price forecast or stock price prediction for THERANEXUS SADIR stock?

9 analysts have analysed ALTHX.PA and the average price target is 6.32 EUR. This implies a price increase of 1190.61% is expected in the next year compared to the current price of 0.49. Check the THERANEXUS SADIR stock analysts ratings, price target forecast and up-and down grades for more detailed information.


What is THERANEXUS SADIR worth?

THERANEXUS SADIR (ALTHX.PA) has a market capitalization of 3.80M EUR. This makes ALTHX.PA a Nano Cap stock.


How many employees does THERANEXUS SADIR have?

THERANEXUS SADIR (ALTHX.PA) currently has 17 employees.


What are the support and resistance levels for THERANEXUS SADIR (ALTHX.PA) stock?

THERANEXUS SADIR (ALTHX.PA) has a support level at 0.46 and a resistance level at 0.5. Check the full technical report for a detailed analysis of ALTHX.PA support and resistance levels.


Should I buy THERANEXUS SADIR (ALTHX.PA) stock?

There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:


Does THERANEXUS SADIR (ALTHX.PA) stock pay dividends?

ALTHX.PA does not pay a dividend.


When does THERANEXUS SADIR (ALTHX.PA) report earnings?

THERANEXUS SADIR (ALTHX.PA) will report earnings on 2025-04-29, after the market close.


What is the Price/Earnings (PE) ratio of THERANEXUS SADIR (ALTHX.PA)?

THERANEXUS SADIR (ALTHX.PA) does not have a PE ratio as the earnings reported over the last twelve months were negative (-0.4).


ALTHX.PA Technical Analysis


Chartmill TA Rating
Chartmill Setup Rating

ALTHX.PA Fundamental Analysis

ChartMill assigns a fundamental rating of 1 / 10 to ALTHX.PA. ALTHX.PA may be in some trouble as it scores bad on both profitability and health.


Chartmill FA Analysis
Valuation
Growth
Profitability
Health
Dividend

ALTHX.PA Financial Highlights

Over the last trailing twelve months ALTHX.PA reported a non-GAAP Earnings per Share(EPS) of -0.4. The EPS increased by 68.48% compared to the year before.


Industry RankSector Rank
PM (TTM) N/A
ROA -72.26%
ROE N/A
Debt/Equity N/A
Chartmill High Growth Momentum
EPS Q2Q%101.91%
Sales Q2Q%N/A
EPS 1Y (TTM)68.48%
Revenue 1Y (TTM)N/A

ALTHX.PA Ownership and Analysts

ChartMill assigns a Buy % Consensus number of 87% to ALTHX.PA. The Buy consensus is the average rating of analysts ratings from 9 analysts.


Ownership
Inst Owners9.44%
Ins Owners9.44%
Short Float %N/A
Short RatioN/A
Analysts
Analysts86.67
Price Target6.32 (1189.8%)
EPS Next Y-0.5%
Revenue Next YearN/A